A multicenter, nonrandomized, open-label, single-arm phase II trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Konecny, G., Finkler, N., Lee, P., Yovine, A., Liu, A., Sen, P., Squires, M., Kay, A.

Publication Date

  • March 1, 2012

webpage

published in

category

start page

  • S80

end page

  • S80

volume

  • 125

WoS Citations

  • 1

WoS References

  • 0